Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancerPaolo Tarantino(Harvard University), Sara M. Tolaney(Harvard University)npj Precision OncologyMarch 13, 202610.1038/s41698-026-01365-6Cited by 0SaveCiteExport RISWatch citationsRelated PapersAndrogen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer|npj Breast Cancer|2026|0